Penumbra, Inc. (PEN)

Market Cap	12.51B +25.5%
Revenue (ttm)	1.50B +17.6%
Net Income	160.59M +8.7%
EPS	4.07 +8.8%
Shares Out	39.39M
PE Ratio	78.06
Forward PE	57.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	379,359
Open	316.61
Previous Close	316.35
Day's Range	316.53 - 317.52
52-Week Range	221.26 - 362.41
Beta	0.70
Analysts	Hold
Price Target	361.58 (+13.88%)
Est. Earnings	Nov 4, 2026

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,700
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Financial Performance

In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.

Analyst Summary

According to 16 analysts, the average rating for PEN stock is "Hold." The 12-month stock price target is $361.58, which is an increase of 13.88% from the latest price.

Price Target

$361.58

(13.88% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 9, 2026

Data Sources Report a data error